Literature DB >> 30445167

Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model.

Layal El-Hajjar1, Nour Jalaleddine1, Abdullah Shaito2, Kazem Zibara3, Jalal M Kazan4, Jamal El-Saghir5, Marwan El-Sabban6.   

Abstract

BACKGROUND: Bevacizumab or Avastin® (Av) is an anti-vascular endothelial growth factor agent. It does not improve survival of breast cancer patients due to development of refractoriness. Av treatment was shown to increase inflammation in a diabetic mouse model, and also to induce epithelial-to-mesenchymal transition of non-transformed breast epithelia. This study aimed to understand if the Av-induced inflammatory microenvironment could be a mechanism of Av refractoriness. Expression profiles of inflammatory mediators, in vitro in MDA-MB-231 cells, in vivo in a mouse model xenografted with MDA-MB-231 cells and from archived cases of human breast carcinoma tissues were evaluated. Gap junctions are also crucial for angiogenesis and tumor cell extravasation. The effect of connexin 43 (Cx43) overexpression on the expression of inflammatory markers in MDA-MB-231 cells treated with Av was assessed.
METHODS: MDA-MB-231 cells, control or overexpressing Cx43, were used in this study. Proliferation and invasion assays were performed. Quantitative PCR, ELISA and western blotting were performed to assess the regulation of inflammatory mediators and other factors upon Av treatment. Immunofluorescence was performed to document the translocation of Nuclear Factor-kappa B p65.
RESULTS: Breast cancer tissues had elevated transcriptional levels of inflammatory mediators. Av treatment increased expression levels of inflammatory mediators and metastatic factors in vitro and in vivo. Interestingly, overexpressing Cx43 in MDA-MB-231 cells alleviated the inflammatory effects induced by Av treatment.
CONCLUSION: This study attributes Av refractoriness to the Av therapy-induced inflammatory microenvironment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Breast cancer; Connexin 43; Inflammation; Metastasis; NF-κB

Mesh:

Substances:

Year:  2018        PMID: 30445167     DOI: 10.1016/j.cellsig.2018.11.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  3 in total

Review 1.  Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.

Authors:  Samuel S Widodo; Ryan A Hutchinson; Yitong Fang; Stefano Mangiola; Paul J Neeson; Phillip K Darcy; Alexander D Barrow; Christopher M Hovens; Marija Dinevska; Stanley S Stylli; Theo Mantamadiotis
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

2.  P53: The endothelium defender.

Authors:  Mohammad Afaz Uddin; Nektarios Barabutis
Journal:  J Cell Biochem       Date:  2019-02-28       Impact factor: 4.429

3.  D-Dimer Is a Predictive Factor of Cancer Therapeutics-Related Cardiac Dysfunction in Patients Treated With Cardiotoxic Chemotherapy.

Authors:  Masayoshi Oikawa; Daiki Yaegashi; Tetsuro Yokokawa; Tomofumi Misaka; Takamasa Sato; Takashi Kaneshiro; Atsushi Kobayashi; Akiomi Yoshihisa; Kazuhiko Nakazato; Takafumi Ishida; Yasuchika Takeishi
Journal:  Front Cardiovasc Med       Date:  2022-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.